nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—ABCB1—melanoma	0.198	1	CbGaD
Methadone—CYP1A2—Carmustine—melanoma	0.0885	0.156	CbGbCtD
Methadone—CYP1A2—Vemurafenib—melanoma	0.07	0.124	CbGbCtD
Methadone—CYP3A4—Temozolomide—melanoma	0.0669	0.118	CbGbCtD
Methadone—CYP2D6—Vemurafenib—melanoma	0.0576	0.102	CbGbCtD
Methadone—CYP1A2—Dacarbazine—melanoma	0.0536	0.0948	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.043	0.076	CbGbCtD
Methadone—CYP3A7—Docetaxel—melanoma	0.043	0.076	CbGbCtD
Methadone—ABCB1—Dactinomycin—melanoma	0.0407	0.0719	CbGbCtD
Methadone—CYP3A4—Vemurafenib—melanoma	0.0367	0.0648	CbGbCtD
Methadone—CYP3A5—Docetaxel—melanoma	0.0323	0.057	CbGbCtD
Methadone—ABCB1—Docetaxel—melanoma	0.021	0.0371	CbGbCtD
Methadone—CYP3A4—Docetaxel—melanoma	0.0126	0.0222	CbGbCtD
Methadone—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.0038	0.0354	CcSEcCtD
Methadone—Intracranial pressure increased—Carmustine—melanoma	0.00309	0.0288	CcSEcCtD
Methadone—Hypomagnesaemia—Bleomycin—melanoma	0.00233	0.0217	CcSEcCtD
Methadone—Lung disorder—Temozolomide—melanoma	0.00176	0.0164	CcSEcCtD
Methadone—Amenorrhoea—Temozolomide—melanoma	0.00142	0.0132	CcSEcCtD
Methadone—Lacrimation—Docetaxel—melanoma	0.00141	0.0131	CcSEcCtD
Methadone—Drug interaction—Carmustine—melanoma	0.00139	0.013	CcSEcCtD
Methadone—Weight decreased—Vemurafenib—melanoma	0.00139	0.0129	CcSEcCtD
Methadone—Phlebitis—Bleomycin—melanoma	0.00125	0.0116	CcSEcCtD
Methadone—Redness—Docetaxel—melanoma	0.00123	0.0114	CcSEcCtD
Methadone—Disorientation—Bleomycin—melanoma	0.0012	0.0112	CcSEcCtD
Methadone—Phlebitis—Dactinomycin—melanoma	0.00116	0.0108	CcSEcCtD
Methadone—Chills—Vemurafenib—melanoma	0.0011	0.0102	CcSEcCtD
Methadone—Phlebitis—Carmustine—melanoma	0.00109	0.0101	CcSEcCtD
Methadone—Erythema—Vemurafenib—melanoma	0.00107	0.00994	CcSEcCtD
Methadone—Swelling—Carmustine—melanoma	0.00106	0.00989	CcSEcCtD
Methadone—Rhinorrhoea—Docetaxel—melanoma	0.00102	0.00954	CcSEcCtD
Methadone—Amenorrhoea—Docetaxel—melanoma	0.000944	0.0088	CcSEcCtD
Methadone—Lacrimation increased—Docetaxel—melanoma	0.0009	0.00839	CcSEcCtD
Methadone—Drug interaction—Docetaxel—melanoma	0.000894	0.00833	CcSEcCtD
Methadone—Anaphylactic shock—Vemurafenib—melanoma	0.000871	0.00811	CcSEcCtD
Methadone—Hypokalaemia—Carmustine—melanoma	0.000853	0.00794	CcSEcCtD
Methadone—Weight decreased—Bleomycin—melanoma	0.000839	0.00782	CcSEcCtD
Methadone—Hypokalaemia—Temozolomide—melanoma	0.000824	0.00768	CcSEcCtD
Methadone—Hypotension—Vemurafenib—melanoma	0.000814	0.00758	CcSEcCtD
Methadone—Sweating increased—Temozolomide—melanoma	0.000762	0.0071	CcSEcCtD
Methadone—Decreased appetite—Vemurafenib—melanoma	0.000757	0.00705	CcSEcCtD
Methadone—Constipation—Vemurafenib—melanoma	0.000745	0.00694	CcSEcCtD
Methadone—Lightheadedness—Docetaxel—melanoma	0.000742	0.00691	CcSEcCtD
Methadone—Pulmonary oedema—Docetaxel—melanoma	0.000738	0.00688	CcSEcCtD
Methadone—Weight increased—Temozolomide—melanoma	0.000712	0.00664	CcSEcCtD
Methadone—Weight decreased—Temozolomide—melanoma	0.000708	0.0066	CcSEcCtD
Methadone—Phlebitis—Docetaxel—melanoma	0.000699	0.00651	CcSEcCtD
Methadone—Clotrimazole—CYP17A1—melanoma	0.000691	0.268	CrCbGaD
Methadone—Flushing—Bleomycin—melanoma	0.000689	0.00642	CcSEcCtD
Methadone—Body temperature increased—Vemurafenib—melanoma	0.000688	0.00641	CcSEcCtD
Methadone—Swelling—Docetaxel—melanoma	0.000682	0.00636	CcSEcCtD
Methadone—Chills—Bleomycin—melanoma	0.000666	0.00621	CcSEcCtD
Methadone—Erythema—Bleomycin—melanoma	0.000646	0.00602	CcSEcCtD
Methadone—Hallucination—Carmustine—melanoma	0.000645	0.00601	CcSEcCtD
Methadone—Flushing—Dactinomycin—melanoma	0.000643	0.00599	CcSEcCtD
Methadone—Hypersensitivity—Vemurafenib—melanoma	0.000642	0.00598	CcSEcCtD
Methadone—Visual disturbance—Docetaxel—melanoma	0.000635	0.00592	CcSEcCtD
Methadone—Asthenia—Vemurafenib—melanoma	0.000625	0.00582	CcSEcCtD
Methadone—Visual impairment—Carmustine—melanoma	0.000625	0.00582	CcSEcCtD
Methadone—Hallucination—Temozolomide—melanoma	0.000623	0.00581	CcSEcCtD
Methadone—Chills—Dactinomycin—melanoma	0.000621	0.00579	CcSEcCtD
Methadone—Cardiac failure—Docetaxel—melanoma	0.000617	0.00575	CcSEcCtD
Methadone—Pruritus—Vemurafenib—melanoma	0.000616	0.00574	CcSEcCtD
Methadone—Visual impairment—Temozolomide—melanoma	0.000604	0.00562	CcSEcCtD
Methadone—Erythema—Dactinomycin—melanoma	0.000603	0.00562	CcSEcCtD
Methadone—Flushing—Carmustine—melanoma	0.000602	0.0056	CcSEcCtD
Methadone—Diarrhoea—Vemurafenib—melanoma	0.000596	0.00555	CcSEcCtD
Methadone—Flushing—Temozolomide—melanoma	0.000581	0.00542	CcSEcCtD
Methadone—Arrhythmia—Carmustine—melanoma	0.000579	0.00539	CcSEcCtD
Methadone—Dizziness—Vemurafenib—melanoma	0.000576	0.00536	CcSEcCtD
Methadone—Erythema—Carmustine—melanoma	0.000564	0.00526	CcSEcCtD
Methadone—Chills—Temozolomide—melanoma	0.000562	0.00524	CcSEcCtD
Methadone—Vomiting—Vemurafenib—melanoma	0.000554	0.00516	CcSEcCtD
Methadone—Orthostatic hypotension—Docetaxel—melanoma	0.00055	0.00512	CcSEcCtD
Methadone—Rash—Vemurafenib—melanoma	0.000549	0.00512	CcSEcCtD
Methadone—Dermatitis—Vemurafenib—melanoma	0.000548	0.00511	CcSEcCtD
Methadone—Headache—Vemurafenib—melanoma	0.000545	0.00508	CcSEcCtD
Methadone—Erythema—Temozolomide—melanoma	0.000545	0.00508	CcSEcCtD
Methadone—Nasopharyngitis—Docetaxel—melanoma	0.000538	0.00502	CcSEcCtD
Methadone—Confusional state—Bleomycin—melanoma	0.000532	0.00496	CcSEcCtD
Methadone—Tremor—Carmustine—melanoma	0.000529	0.00493	CcSEcCtD
Methadone—Oedema—Bleomycin—melanoma	0.000528	0.00492	CcSEcCtD
Methadone—Anaphylactic shock—Bleomycin—melanoma	0.000528	0.00492	CcSEcCtD
Methadone—Agitation—Carmustine—melanoma	0.000518	0.00483	CcSEcCtD
Methadone—Nausea—Vemurafenib—melanoma	0.000517	0.00482	CcSEcCtD
Methadone—Thrombocytopenia—Bleomycin—melanoma	0.000517	0.00481	CcSEcCtD
Methadone—Tremor—Temozolomide—melanoma	0.000511	0.00476	CcSEcCtD
Methadone—Anorexia—Bleomycin—melanoma	0.000503	0.00469	CcSEcCtD
Methadone—Agitation—Temozolomide—melanoma	0.000501	0.00467	CcSEcCtD
Methadone—Hypotension—Bleomycin—melanoma	0.000493	0.00459	CcSEcCtD
Methadone—Oedema—Dactinomycin—melanoma	0.000492	0.00458	CcSEcCtD
Methadone—Vertigo—Temozolomide—melanoma	0.00049	0.00456	CcSEcCtD
Methadone—Convulsion—Carmustine—melanoma	0.000489	0.00455	CcSEcCtD
Methadone—Palpitations—Temozolomide—melanoma	0.000482	0.00449	CcSEcCtD
Methadone—Thrombocytopenia—Dactinomycin—melanoma	0.000482	0.00449	CcSEcCtD
Methadone—Anxiety—Carmustine—melanoma	0.000479	0.00446	CcSEcCtD
Methadone—Weight increased—Docetaxel—melanoma	0.000474	0.00441	CcSEcCtD
Methadone—Convulsion—Temozolomide—melanoma	0.000472	0.0044	CcSEcCtD
Methadone—Weight decreased—Docetaxel—melanoma	0.000471	0.00439	CcSEcCtD
Methadone—Anorexia—Dactinomycin—melanoma	0.000469	0.00437	CcSEcCtD
Methadone—Confusional state—Carmustine—melanoma	0.000464	0.00433	CcSEcCtD
Methadone—Anxiety—Temozolomide—melanoma	0.000463	0.00431	CcSEcCtD
Methadone—Oedema—Carmustine—melanoma	0.00046	0.00429	CcSEcCtD
Methadone—Decreased appetite—Bleomycin—melanoma	0.000459	0.00427	CcSEcCtD
Methadone—Dry mouth—Temozolomide—melanoma	0.000454	0.00423	CcSEcCtD
Methadone—Pain—Bleomycin—melanoma	0.000451	0.0042	CcSEcCtD
Methadone—Thrombocytopenia—Carmustine—melanoma	0.000451	0.0042	CcSEcCtD
Methadone—Tachycardia—Carmustine—melanoma	0.000449	0.00419	CcSEcCtD
Methadone—Confusional state—Temozolomide—melanoma	0.000449	0.00418	CcSEcCtD
Methadone—Anaphylactic shock—Temozolomide—melanoma	0.000445	0.00415	CcSEcCtD
Methadone—Oedema—Temozolomide—melanoma	0.000445	0.00415	CcSEcCtD
Methadone—Anorexia—Carmustine—melanoma	0.000439	0.00409	CcSEcCtD
Methadone—Thrombocytopenia—Temozolomide—melanoma	0.000436	0.00406	CcSEcCtD
Methadone—Feeling abnormal—Bleomycin—melanoma	0.000435	0.00405	CcSEcCtD
Methadone—Hypotension—Carmustine—melanoma	0.00043	0.00401	CcSEcCtD
Methadone—Hyperhidrosis—Temozolomide—melanoma	0.00043	0.00401	CcSEcCtD
Methadone—Decreased appetite—Dactinomycin—melanoma	0.000428	0.00398	CcSEcCtD
Methadone—Anorexia—Temozolomide—melanoma	0.000424	0.00395	CcSEcCtD
Methadone—Pain—Dactinomycin—melanoma	0.000421	0.00392	CcSEcCtD
Methadone—Urticaria—Bleomycin—melanoma	0.000419	0.0039	CcSEcCtD
Methadone—Body temperature increased—Bleomycin—melanoma	0.000417	0.00389	CcSEcCtD
Methadone—Insomnia—Carmustine—melanoma	0.000416	0.00388	CcSEcCtD
Methadone—Somnolence—Carmustine—melanoma	0.000409	0.00381	CcSEcCtD
Methadone—Feeling abnormal—Dactinomycin—melanoma	0.000405	0.00378	CcSEcCtD
Methadone—Insomnia—Temozolomide—melanoma	0.000402	0.00375	CcSEcCtD
Methadone—Gastrointestinal pain—Dactinomycin—melanoma	0.000402	0.00375	CcSEcCtD
Methadone—Visual impairment—Docetaxel—melanoma	0.000401	0.00374	CcSEcCtD
Methadone—Decreased appetite—Carmustine—melanoma	0.0004	0.00373	CcSEcCtD
Methadone—Somnolence—Temozolomide—melanoma	0.000396	0.00369	CcSEcCtD
Methadone—Constipation—Carmustine—melanoma	0.000394	0.00367	CcSEcCtD
Methadone—Pain—Carmustine—melanoma	0.000394	0.00367	CcSEcCtD
Methadone—Abdominal pain—Dactinomycin—melanoma	0.000389	0.00362	CcSEcCtD
Methadone—Body temperature increased—Dactinomycin—melanoma	0.000389	0.00362	CcSEcCtD
Methadone—Hypersensitivity—Bleomycin—melanoma	0.000389	0.00362	CcSEcCtD
Methadone—Decreased appetite—Temozolomide—melanoma	0.000387	0.0036	CcSEcCtD
Methadone—Flushing—Docetaxel—melanoma	0.000387	0.0036	CcSEcCtD
Methadone—Constipation—Temozolomide—melanoma	0.000381	0.00355	CcSEcCtD
Methadone—Pain—Temozolomide—melanoma	0.000381	0.00355	CcSEcCtD
Methadone—Feeling abnormal—Carmustine—melanoma	0.000379	0.00354	CcSEcCtD
Methadone—Asthenia—Bleomycin—melanoma	0.000378	0.00353	CcSEcCtD
Methadone—Gastrointestinal pain—Carmustine—melanoma	0.000377	0.00351	CcSEcCtD
Methadone—Chills—Docetaxel—melanoma	0.000374	0.00348	CcSEcCtD
Methadone—Pruritus—Bleomycin—melanoma	0.000373	0.00348	CcSEcCtD
Methadone—Arrhythmia—Docetaxel—melanoma	0.000372	0.00347	CcSEcCtD
Methadone—Feeling abnormal—Temozolomide—melanoma	0.000367	0.00342	CcSEcCtD
Methadone—Body temperature increased—Carmustine—melanoma	0.000364	0.00339	CcSEcCtD
Methadone—Abdominal pain—Carmustine—melanoma	0.000364	0.00339	CcSEcCtD
Methadone—Gastrointestinal pain—Temozolomide—melanoma	0.000364	0.00339	CcSEcCtD
Methadone—Erythema—Docetaxel—melanoma	0.000363	0.00338	CcSEcCtD
Methadone—Hypersensitivity—Dactinomycin—melanoma	0.000362	0.00338	CcSEcCtD
Methadone—Orphenadrine—SCN10A—melanoma	0.00036	0.139	CrCbGaD
Methadone—Urticaria—Temozolomide—melanoma	0.000354	0.00329	CcSEcCtD
Methadone—Asthenia—Dactinomycin—melanoma	0.000353	0.00329	CcSEcCtD
Methadone—Abdominal pain—Temozolomide—melanoma	0.000352	0.00328	CcSEcCtD
Methadone—Body temperature increased—Temozolomide—melanoma	0.000352	0.00328	CcSEcCtD
Methadone—Muscle spasms—Docetaxel—melanoma	0.000349	0.00325	CcSEcCtD
Methadone—Hypersensitivity—Carmustine—melanoma	0.000339	0.00316	CcSEcCtD
Methadone—Diarrhoea—Dactinomycin—melanoma	0.000337	0.00314	CcSEcCtD
Methadone—Vomiting—Bleomycin—melanoma	0.000335	0.00313	CcSEcCtD
Methadone—Rash—Bleomycin—melanoma	0.000333	0.0031	CcSEcCtD
Methadone—Dermatitis—Bleomycin—melanoma	0.000332	0.0031	CcSEcCtD
Methadone—Asthenia—Carmustine—melanoma	0.00033	0.00308	CcSEcCtD
Methadone—Hypersensitivity—Temozolomide—melanoma	0.000328	0.00305	CcSEcCtD
Methadone—Syncope—Docetaxel—melanoma	0.000325	0.00303	CcSEcCtD
Methadone—Palpitations—Docetaxel—melanoma	0.00032	0.00299	CcSEcCtD
Methadone—Asthenia—Temozolomide—melanoma	0.000319	0.00297	CcSEcCtD
Methadone—Loss of consciousness—Docetaxel—melanoma	0.000319	0.00297	CcSEcCtD
Methadone—Diarrhoea—Carmustine—melanoma	0.000315	0.00294	CcSEcCtD
Methadone—Pruritus—Temozolomide—melanoma	0.000315	0.00293	CcSEcCtD
Methadone—Convulsion—Docetaxel—melanoma	0.000314	0.00293	CcSEcCtD
Methadone—Nausea—Bleomycin—melanoma	0.000313	0.00292	CcSEcCtD
Methadone—Vomiting—Dactinomycin—melanoma	0.000313	0.00291	CcSEcCtD
Methadone—Rash—Dactinomycin—melanoma	0.00031	0.00289	CcSEcCtD
Methadone—Dizziness—Carmustine—melanoma	0.000305	0.00284	CcSEcCtD
Methadone—Diarrhoea—Temozolomide—melanoma	0.000304	0.00284	CcSEcCtD
Methadone—Dry mouth—Docetaxel—melanoma	0.000302	0.00281	CcSEcCtD
Methadone—Confusional state—Docetaxel—melanoma	0.000298	0.00278	CcSEcCtD
Methadone—Oedema—Docetaxel—melanoma	0.000296	0.00276	CcSEcCtD
Methadone—Anaphylactic shock—Docetaxel—melanoma	0.000296	0.00276	CcSEcCtD
Methadone—Dizziness—Temozolomide—melanoma	0.000294	0.00274	CcSEcCtD
Methadone—Vomiting—Carmustine—melanoma	0.000293	0.00273	CcSEcCtD
Methadone—Nausea—Dactinomycin—melanoma	0.000292	0.00272	CcSEcCtD
Methadone—Shock—Docetaxel—melanoma	0.000291	0.00271	CcSEcCtD
Methadone—Rash—Carmustine—melanoma	0.00029	0.00271	CcSEcCtD
Methadone—Dermatitis—Carmustine—melanoma	0.00029	0.0027	CcSEcCtD
Methadone—Thrombocytopenia—Docetaxel—melanoma	0.00029	0.0027	CcSEcCtD
Methadone—Tachycardia—Docetaxel—melanoma	0.000289	0.00269	CcSEcCtD
Methadone—Headache—Carmustine—melanoma	0.000288	0.00269	CcSEcCtD
Methadone—Tamoxifen—CYP1B1—melanoma	0.000283	0.11	CrCbGaD
Methadone—Vomiting—Temozolomide—melanoma	0.000283	0.00264	CcSEcCtD
Methadone—Anorexia—Docetaxel—melanoma	0.000282	0.00263	CcSEcCtD
Methadone—Rash—Temozolomide—melanoma	0.000281	0.00261	CcSEcCtD
Methadone—Dermatitis—Temozolomide—melanoma	0.00028	0.00261	CcSEcCtD
Methadone—Headache—Temozolomide—melanoma	0.000279	0.0026	CcSEcCtD
Methadone—Hypotension—Docetaxel—melanoma	0.000277	0.00258	CcSEcCtD
Methadone—Nausea—Carmustine—melanoma	0.000274	0.00255	CcSEcCtD
Methadone—Oxaprozin—PTGS2—melanoma	0.000273	0.106	CrCbGaD
Methadone—Insomnia—Docetaxel—melanoma	0.000268	0.00249	CcSEcCtD
Methadone—Nausea—Temozolomide—melanoma	0.000264	0.00246	CcSEcCtD
Methadone—Somnolence—Docetaxel—melanoma	0.000263	0.00245	CcSEcCtD
Methadone—Decreased appetite—Docetaxel—melanoma	0.000257	0.0024	CcSEcCtD
Methadone—Pain—Docetaxel—melanoma	0.000253	0.00236	CcSEcCtD
Methadone—Constipation—Docetaxel—melanoma	0.000253	0.00236	CcSEcCtD
Methadone—Feeling abnormal—Docetaxel—melanoma	0.000244	0.00227	CcSEcCtD
Methadone—Gastrointestinal pain—Docetaxel—melanoma	0.000242	0.00225	CcSEcCtD
Methadone—Abdominal pain—Docetaxel—melanoma	0.000234	0.00218	CcSEcCtD
Methadone—Body temperature increased—Docetaxel—melanoma	0.000234	0.00218	CcSEcCtD
Methadone—Hypersensitivity—Docetaxel—melanoma	0.000218	0.00203	CcSEcCtD
Methadone—Asthenia—Docetaxel—melanoma	0.000212	0.00198	CcSEcCtD
Methadone—Pruritus—Docetaxel—melanoma	0.000209	0.00195	CcSEcCtD
Methadone—Diarrhoea—Docetaxel—melanoma	0.000202	0.00189	CcSEcCtD
Methadone—Dizziness—Docetaxel—melanoma	0.000196	0.00182	CcSEcCtD
Methadone—Vomiting—Docetaxel—melanoma	0.000188	0.00175	CcSEcCtD
Methadone—Rash—Docetaxel—melanoma	0.000187	0.00174	CcSEcCtD
Methadone—Dermatitis—Docetaxel—melanoma	0.000186	0.00174	CcSEcCtD
Methadone—Headache—Docetaxel—melanoma	0.000185	0.00173	CcSEcCtD
Methadone—Phenylbutazone—PTGS2—melanoma	0.00018	0.0699	CrCbGaD
Methadone—Fexofenadine—ABCB1—melanoma	0.000178	0.0689	CrCbGaD
Methadone—Nausea—Docetaxel—melanoma	0.000176	0.00164	CcSEcCtD
Methadone—Clotrimazole—ABCB1—melanoma	0.000137	0.0533	CrCbGaD
Methadone—Fentanyl—ABCB1—melanoma	0.000118	0.0455	CrCbGaD
Methadone—Loperamide—ABCB1—melanoma	0.000113	0.0439	CrCbGaD
Methadone—Trimipramine—ABCB1—melanoma	8.5e-05	0.0329	CrCbGaD
Methadone—Promethazine—ABCB1—melanoma	8.19e-05	0.0317	CrCbGaD
Methadone—Tamoxifen—ABCB1—melanoma	8.13e-05	0.0315	CrCbGaD
Methadone—OPRM1—Signaling by GPCR—MAPK3—melanoma	9.59e-06	7.58e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	9.59e-06	7.58e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—SLC5A5—melanoma	9.55e-06	7.55e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CASP3—melanoma	9.52e-06	7.53e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2—melanoma	9.51e-06	7.52e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PRKCA—melanoma	9.5e-06	7.51e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CYP1B1—melanoma	9.46e-06	7.48e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—melanoma	9.46e-06	7.48e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ERCC2—melanoma	9.43e-06	7.45e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—BRAF—melanoma	9.41e-06	7.44e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—PIK3CA—melanoma	9.37e-06	7.41e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MDM2—melanoma	9.33e-06	7.38e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CD44—melanoma	9.3e-06	7.35e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GNAQ—melanoma	9.3e-06	7.35e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCND1—melanoma	9.27e-06	7.33e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GNAQ—melanoma	9.22e-06	7.29e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CD44—melanoma	9.22e-06	7.29e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ERBB2—melanoma	9.2e-06	7.27e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CTNNB1—melanoma	9.18e-06	7.26e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IGF1—melanoma	9.17e-06	7.25e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PLA2G6—melanoma	9.14e-06	7.23e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—MAPK1—melanoma	9.12e-06	7.21e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—melanoma	9.12e-06	7.21e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CB—melanoma	9.09e-06	7.18e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CB—melanoma	9.08e-06	7.18e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CD—melanoma	9.05e-06	7.16e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.03e-06	7.14e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—melanoma	9e-06	7.12e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—melanoma	9e-06	7.11e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CYP17A1—melanoma	8.97e-06	7.1e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CDKN1A—melanoma	8.97e-06	7.09e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8.95e-06	7.07e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTEN—melanoma	8.95e-06	7.07e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ABCB1—melanoma	8.94e-06	7.07e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ALB—melanoma	8.94e-06	7.07e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CYP1B1—melanoma	8.92e-06	7.05e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NFKB1—melanoma	8.9e-06	7.04e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAP2K1—melanoma	8.86e-06	7.01e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	8.85e-06	7e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CYP1B1—melanoma	8.84e-06	6.99e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CD—melanoma	8.8e-06	6.96e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	8.74e-06	6.91e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AKT1—melanoma	8.73e-06	6.9e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—melanoma	8.72e-06	6.9e-05	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	8.72e-06	6.89e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—HRAS—melanoma	8.67e-06	6.85e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—KRAS—melanoma	8.62e-06	6.81e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.56e-06	6.77e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CDKN1B—melanoma	8.52e-06	6.74e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GNA11—melanoma	8.48e-06	6.7e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—FGF2—melanoma	8.43e-06	6.66e-05	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AKT1—melanoma	8.43e-06	6.66e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CASP3—melanoma	8.35e-06	6.6e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2—melanoma	8.34e-06	6.59e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—melanoma	8.3e-06	6.56e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—FASN—melanoma	8.29e-06	6.56e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PRKCA—melanoma	8.23e-06	6.51e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—VCAN—melanoma	8.21e-06	6.49e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ERCC2—melanoma	8.16e-06	6.45e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SLC5A5—melanoma	8.16e-06	6.45e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCND1—melanoma	8.13e-06	6.43e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—melanoma	8.08e-06	6.39e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CTNNB1—melanoma	8.05e-06	6.36e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—melanoma	8e-06	6.33e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ABCB1—melanoma	7.98e-06	6.31e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NRAS—melanoma	7.98e-06	6.31e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—PIK3CA—melanoma	7.92e-06	6.26e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CB—melanoma	7.89e-06	6.24e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—melanoma	7.89e-06	6.24e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MDM2—melanoma	7.89e-06	6.23e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GNAQ—melanoma	7.88e-06	6.23e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CD44—melanoma	7.88e-06	6.23e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CDKN1A—melanoma	7.86e-06	6.22e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTEN—melanoma	7.85e-06	6.21e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTEN—melanoma	7.84e-06	6.2e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—melanoma	7.82e-06	6.18e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NFKB1—melanoma	7.81e-06	6.17e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.8e-06	6.17e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ERBB2—melanoma	7.77e-06	6.15e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.72e-06	6.1e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CB—melanoma	7.67e-06	6.07e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AKT1—melanoma	7.65e-06	6.05e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.65e-06	6.04e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK3—melanoma	7.64e-06	6.04e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CG—melanoma	7.62e-06	6.02e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CYP1B1—melanoma	7.55e-06	5.97e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CG—melanoma	7.44e-06	5.89e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MYC—melanoma	7.43e-06	5.88e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—melanoma	7.37e-06	5.83e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—melanoma	7.35e-06	5.81e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PRKCA—melanoma	7.35e-06	5.81e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ABCB1—melanoma	7.34e-06	5.81e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—HRAS—melanoma	7.32e-06	5.79e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ERCC2—melanoma	7.29e-06	5.76e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ABCB1—melanoma	7.28e-06	5.76e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK1—melanoma	7.27e-06	5.75e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—melanoma	7.27e-06	5.75e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PIK3CA—melanoma	7.24e-06	5.72e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CDKN1B—melanoma	7.2e-06	5.69e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—melanoma	7.18e-06	5.68e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PRKCA—melanoma	7.17e-06	5.67e-05	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AKT1—melanoma	7.12e-06	5.63e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ERCC2—melanoma	7.11e-06	5.62e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—melanoma	7.09e-06	5.6e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CASP3—melanoma	7.06e-06	5.58e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2—melanoma	7.05e-06	5.57e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—melanoma	7.02e-06	5.55e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—melanoma	7.01e-06	5.54e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NRAS—melanoma	7e-06	5.53e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP17A1—melanoma	6.93e-06	5.48e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KRAS—melanoma	6.87e-06	5.43e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCND1—melanoma	6.87e-06	5.43e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTEN—melanoma	6.82e-06	5.39e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CTNNB1—melanoma	6.8e-06	5.38e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.76e-06	5.35e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PRKCA—melanoma	6.76e-06	5.34e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ERCC2—melanoma	6.7e-06	5.3e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK3—melanoma	6.7e-06	5.3e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PRKCA—melanoma	6.7e-06	5.3e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CD—melanoma	6.7e-06	5.29e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—melanoma	6.67e-06	5.27e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.67e-06	5.27e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ERCC2—melanoma	6.64e-06	5.25e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CDKN1A—melanoma	6.64e-06	5.25e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTEN—melanoma	6.63e-06	5.24e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ALB—melanoma	6.61e-06	5.23e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NFKB1—melanoma	6.6e-06	5.22e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CD—melanoma	6.54e-06	5.17e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GNA11—melanoma	6.54e-06	5.17e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MYC—melanoma	6.52e-06	5.15e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AKT1—melanoma	6.47e-06	5.11e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ALB—melanoma	6.46e-06	5.11e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CG—melanoma	6.45e-06	5.1e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—FASN—melanoma	6.4e-06	5.06e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK1—melanoma	6.38e-06	5.04e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—melanoma	6.38e-06	5.04e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CA—melanoma	6.31e-06	4.99e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC5A5—melanoma	6.3e-06	4.98e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—melanoma	6.22e-06	4.92e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ABCB1—melanoma	6.22e-06	4.92e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—melanoma	6.11e-06	4.83e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GNAQ—melanoma	6.08e-06	4.81e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CD44—melanoma	6.08e-06	4.81e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.04e-06	4.77e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KRAS—melanoma	6.02e-06	4.76e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—melanoma	5.99e-06	4.73e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—melanoma	5.93e-06	4.69e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NRAS—melanoma	5.91e-06	4.68e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AKT1—melanoma	5.91e-06	4.67e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—HRAS—melanoma	5.84e-06	4.62e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CB—melanoma	5.84e-06	4.61e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP1B1—melanoma	5.83e-06	4.61e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—melanoma	5.78e-06	4.57e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CG—melanoma	5.76e-06	4.55e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PRKCA—melanoma	5.73e-06	4.53e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CB—melanoma	5.7e-06	4.51e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ERCC2—melanoma	5.68e-06	4.49e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CD—melanoma	5.67e-06	4.48e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK3—melanoma	5.66e-06	4.48e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—melanoma	5.65e-06	4.47e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CG—melanoma	5.62e-06	4.44e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ALB—melanoma	5.6e-06	4.42e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—melanoma	5.59e-06	4.42e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—melanoma	5.55e-06	4.39e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CA—melanoma	5.54e-06	4.38e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CA—melanoma	5.53e-06	4.38e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MYC—melanoma	5.51e-06	4.36e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.5e-06	4.35e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—melanoma	5.42e-06	4.29e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK1—melanoma	5.39e-06	4.26e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—melanoma	5.39e-06	4.26e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—melanoma	5.35e-06	4.23e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CG—melanoma	5.29e-06	4.19e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CG—melanoma	5.25e-06	4.15e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AKT1—melanoma	5.16e-06	4.08e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—HRAS—melanoma	5.12e-06	4.05e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—melanoma	5.11e-06	4.04e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KRAS—melanoma	5.09e-06	4.02e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—melanoma	5.06e-06	4e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CD—melanoma	5.06e-06	4e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTEN—melanoma	5.04e-06	3.99e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ALB—melanoma	4.99e-06	3.95e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CB—melanoma	4.94e-06	3.91e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CD—melanoma	4.94e-06	3.9e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTEN—melanoma	4.93e-06	3.9e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—melanoma	4.9e-06	3.87e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—melanoma	4.9e-06	3.87e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ALB—melanoma	4.87e-06	3.85e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CA—melanoma	4.81e-06	3.8e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ABCB1—melanoma	4.8e-06	3.8e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.7e-06	3.72e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CA—melanoma	4.68e-06	3.7e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CD—melanoma	4.65e-06	3.68e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CD—melanoma	4.61e-06	3.65e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ALB—melanoma	4.59e-06	3.63e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ALB—melanoma	4.55e-06	3.6e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AKT1—melanoma	4.53e-06	3.58e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—melanoma	4.52e-06	3.58e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT1—melanoma	4.52e-06	3.57e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CG—melanoma	4.48e-06	3.55e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PRKCA—melanoma	4.42e-06	3.49e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CB—melanoma	4.41e-06	3.49e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ERCC2—melanoma	4.38e-06	3.46e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—melanoma	4.37e-06	3.45e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—melanoma	4.33e-06	3.42e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HRAS—melanoma	4.33e-06	3.42e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CB—melanoma	4.3e-06	3.4e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTEN—melanoma	4.27e-06	3.38e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—melanoma	4.26e-06	3.37e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—melanoma	4.14e-06	3.27e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CB—melanoma	4.06e-06	3.21e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CB—melanoma	4.02e-06	3.18e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—melanoma	4.02e-06	3.18e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—melanoma	3.98e-06	3.15e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CD—melanoma	3.94e-06	3.12e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AKT1—melanoma	3.93e-06	3.11e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ALB—melanoma	3.89e-06	3.08e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT1—melanoma	3.82e-06	3.02e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTEN—melanoma	3.81e-06	3.01e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTEN—melanoma	3.72e-06	2.94e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CA—melanoma	3.56e-06	2.81e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTEN—melanoma	3.5e-06	2.77e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CA—melanoma	3.48e-06	2.75e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTEN—melanoma	3.47e-06	2.75e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CG—melanoma	3.46e-06	2.74e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CB—melanoma	3.44e-06	2.72e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—melanoma	3.4e-06	2.69e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—melanoma	3.34e-06	2.64e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CD—melanoma	3.04e-06	2.41e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CA—melanoma	3.01e-06	2.38e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ALB—melanoma	3e-06	2.37e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTEN—melanoma	2.97e-06	2.35e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AKT1—melanoma	2.91e-06	2.3e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AKT1—melanoma	2.84e-06	2.25e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CA—melanoma	2.69e-06	2.13e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CB—melanoma	2.65e-06	2.1e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—melanoma	2.63e-06	2.08e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CA—melanoma	2.62e-06	2.07e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CA—melanoma	2.47e-06	1.95e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AKT1—melanoma	2.46e-06	1.95e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CA—melanoma	2.45e-06	1.94e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTEN—melanoma	2.29e-06	1.81e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AKT1—melanoma	2.2e-06	1.74e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AKT1—melanoma	2.14e-06	1.69e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CA—melanoma	2.09e-06	1.66e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AKT1—melanoma	2.02e-06	1.6e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AKT1—melanoma	2e-06	1.58e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AKT1—melanoma	1.71e-06	1.35e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CA—melanoma	1.62e-06	1.28e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AKT1—melanoma	1.32e-06	1.04e-05	CbGpPWpGaD
